Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective

Detalhes bibliográficos
Autor(a) principal: BERTHOLO,Ana Paula
Data de Publicação: 2020
Outros Autores: FRANÇA,Carina, FIORINI,Wilma Silva, Barbosa,Egberto Reis, CURY,Rubens Gisbert
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000400230
Resumo: Abstract Subthalamic nucleus deep brain stimulation (STN DBS) is an established treatment that improves motor fluctuations, dyskinesia, and tremor in Parkinson’s disease (PD). After the surgery, a careful electrode programming strategy and medical management are crucial, because an imbalance between them can compromise the quality of life over time. Clinical management is not straightforward and depends on several perioperative motor and non-motor symptoms. In this study, we review the literature data on acute medical management after STN DBS in PD and propose a clinical algorithm on medical management focused on the patient’s phenotypic profile at the perioperative period. Overall, across the trials, the levodopa equivalent daily dose is reduced by 30 to 50% one year after surgery. In patients taking high doses of dopaminergic drugs or with high risk of impulse control disorders, an initial reduction in dopamine agonists after STN DBS is recommended to avoid the hyperdopaminergic syndrome, particularly hypomania. On the other hand, a rapid reduction of dopaminergic agonists of more than 70% during the first months can lead to dopaminergic agonist withdrawal syndrome, characterized by apathy, pain, and autonomic features. In a subset of patients with severe dyskinesia before surgery, an initial reduction in levodopa seems to be a more reasonable approach. Finally, when the patient’s phenotype before the surgery is the severe parkinsonism (wearing-off) with or without tremor, reduction of the medication after surgery can be more conservative. Individualized medical management following DBS contributes to the ultimate therapy success.
id ABNEURO-1_a96bbeab887f65ce7a5c7df421ae30ea
oai_identifier_str oai:scielo:S0004-282X2020000400230
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspectivedeep brain stimulationmedical managementParkinson’s diseasephenotypesubthalamic nucleusAbstract Subthalamic nucleus deep brain stimulation (STN DBS) is an established treatment that improves motor fluctuations, dyskinesia, and tremor in Parkinson’s disease (PD). After the surgery, a careful electrode programming strategy and medical management are crucial, because an imbalance between them can compromise the quality of life over time. Clinical management is not straightforward and depends on several perioperative motor and non-motor symptoms. In this study, we review the literature data on acute medical management after STN DBS in PD and propose a clinical algorithm on medical management focused on the patient’s phenotypic profile at the perioperative period. Overall, across the trials, the levodopa equivalent daily dose is reduced by 30 to 50% one year after surgery. In patients taking high doses of dopaminergic drugs or with high risk of impulse control disorders, an initial reduction in dopamine agonists after STN DBS is recommended to avoid the hyperdopaminergic syndrome, particularly hypomania. On the other hand, a rapid reduction of dopaminergic agonists of more than 70% during the first months can lead to dopaminergic agonist withdrawal syndrome, characterized by apathy, pain, and autonomic features. In a subset of patients with severe dyskinesia before surgery, an initial reduction in levodopa seems to be a more reasonable approach. Finally, when the patient’s phenotype before the surgery is the severe parkinsonism (wearing-off) with or without tremor, reduction of the medication after surgery can be more conservative. Individualized medical management following DBS contributes to the ultimate therapy success.Academia Brasileira de Neurologia - ABNEURO2020-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000400230Arquivos de Neuro-Psiquiatria v.78 n.4 2020reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x20190188info:eu-repo/semantics/openAccessBERTHOLO,Ana PaulaFRANÇA,CarinaFIORINI,Wilma SilvaBarbosa,Egberto ReisCURY,Rubens Gisberteng2020-04-27T00:00:00Zoai:scielo:S0004-282X2020000400230Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2020-04-27T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
title Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
spellingShingle Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
BERTHOLO,Ana Paula
deep brain stimulation
medical management
Parkinson’s disease
phenotype
subthalamic nucleus
title_short Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
title_full Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
title_fullStr Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
title_full_unstemmed Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
title_sort Medical management after subthalamic stimulation in Parkinson’s disease: a phenotype perspective
author BERTHOLO,Ana Paula
author_facet BERTHOLO,Ana Paula
FRANÇA,Carina
FIORINI,Wilma Silva
Barbosa,Egberto Reis
CURY,Rubens Gisbert
author_role author
author2 FRANÇA,Carina
FIORINI,Wilma Silva
Barbosa,Egberto Reis
CURY,Rubens Gisbert
author2_role author
author
author
author
dc.contributor.author.fl_str_mv BERTHOLO,Ana Paula
FRANÇA,Carina
FIORINI,Wilma Silva
Barbosa,Egberto Reis
CURY,Rubens Gisbert
dc.subject.por.fl_str_mv deep brain stimulation
medical management
Parkinson’s disease
phenotype
subthalamic nucleus
topic deep brain stimulation
medical management
Parkinson’s disease
phenotype
subthalamic nucleus
description Abstract Subthalamic nucleus deep brain stimulation (STN DBS) is an established treatment that improves motor fluctuations, dyskinesia, and tremor in Parkinson’s disease (PD). After the surgery, a careful electrode programming strategy and medical management are crucial, because an imbalance between them can compromise the quality of life over time. Clinical management is not straightforward and depends on several perioperative motor and non-motor symptoms. In this study, we review the literature data on acute medical management after STN DBS in PD and propose a clinical algorithm on medical management focused on the patient’s phenotypic profile at the perioperative period. Overall, across the trials, the levodopa equivalent daily dose is reduced by 30 to 50% one year after surgery. In patients taking high doses of dopaminergic drugs or with high risk of impulse control disorders, an initial reduction in dopamine agonists after STN DBS is recommended to avoid the hyperdopaminergic syndrome, particularly hypomania. On the other hand, a rapid reduction of dopaminergic agonists of more than 70% during the first months can lead to dopaminergic agonist withdrawal syndrome, characterized by apathy, pain, and autonomic features. In a subset of patients with severe dyskinesia before surgery, an initial reduction in levodopa seems to be a more reasonable approach. Finally, when the patient’s phenotype before the surgery is the severe parkinsonism (wearing-off) with or without tremor, reduction of the medication after surgery can be more conservative. Individualized medical management following DBS contributes to the ultimate therapy success.
publishDate 2020
dc.date.none.fl_str_mv 2020-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000400230
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000400230
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282x20190188
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.78 n.4 2020
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212787325763584